Ph3 double blind study of JNJ-78278343 for metastatic castration resistant prostate cancer
Phase III Clinical Trial
Trial Number: 78278343PCR3001 (KLK2-comPAS) Protocol Title: A Phase 3 Randomized Double-blind Placebo-controlled Study of Pasritamig (JNJ-78278343) a T cell redirecting Agent Targeting Human Kallikrein 2 + Best Supportive Care Versus Best Supportive Care for Metastatic Castration-resistant Prostate Cancer.